hereditary cancer

The researchers profiled 44 cancer-related genes in 191 individuals with familial breast cancer, colorectal cancer, or other forms of early-onset cancer.

Doctors can now order the test to identify breast cancer patients with BRCA1/2 mutations who may be eligible for surgery or targeted therapy.

The firm generated $56.5 million in revenue compared to $37.4 million in Q3 2018, and beat the consensus Wall Street estimate of $55.0 million

The company had a challenging fiscal first quarter due to the deletion of CPT codes that payors used to use to reimburse hereditary cancer testing. 

CMS has attempted to address stakeholders' concerns about its coverage criteria for germline NGS testing in a new proposed national policy.

Within the program, Ochsner is hoping to improve preventive care in certain cancer and cardiac conditions with information from genetic tests performed by Color.

Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.